Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials

BACKGROUND: Renal impairment is not a consistently cited risk factor for recurrent Clostridioides difficile infection (rCDI). We examined the association between renal impairment and rCDI and the effect of bezlotoxumab, an anti–toxin B monoclonal antibody, in reducing rCDI in participants with renal...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Open Forum Infect Dis
Hlavní autoři: Golan, Yoav, DuPont, Herbert L, Aldomiro, Fernando, Jensen, Erin H, Hanson, Mary E, Dorr, Mary Beth
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Major Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7357450/
https://ncbi.nlm.nih.gov/pubmed/32685606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa248
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky